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Abstract
Background: The aim of this prospective study was to evaluate the effectiveness of extracorporeal shock wave
therapy (ESWT) in normalizing the symptoms and imaging features of primary bone marrow edema syndrome
(BMES) of the knee.
Methods: This study compared the outcomes of ESWT (Group A) (n = 20) and intravenously applied prostacyclin
and bisphosphonate (Group B) (n = 20) in the treatment of BMES of the knee in our department between 2011 and
2013. The Visual Analog Scale for pain (VAS, 100 mm), the Western Ontario and McMaster University Osteoarthritis
Index (WOMAC), the SF-36 scores and MRI scans as well as plain radiographs were obtained before and after therapy
between two groups.
Results: Compared with Group B, we found greater improvement in VAS, the WOMAC Osteoarthritis Index and
SF-36 score at 1, 3 and 6 months post-treatment in Group A (P < 0.05). Furthermore, MRI scans showed a higher
incidence of distinct reduction and complete regression of bone marrow edema at 6 months in Group A (95 vs.
65 %; P = 0.018). The MRI at 1 year follow-up showed complete regression in all patients in Group A. However,
two cases in Group B continued to normalize over the subsequent follow-up period.
Conclusions: ESWT can produce rapid pain relief and functional improvement. It may be an effective, reliable,
and non-invasive technique for rapid treatment of BMES of the knee.
Trial registration: Research Registry UIN 528, September 03, 2015.
Keywords: Bone marrow edema syndrome, Extracorporeal shock wave therapy, Knee, Conservative treatment,
Magnetic resonance imaging
Background
Primary bone marrow edema syndrome (BMES) repre-
sents a reversible but highly painful increase in intersti-
tial fluid [1, 2]. It is a common finding in MR-imaging of
patients with joint pain following largely non-diagnostic
or normal radiographs. Although various vascular factors
are known to contribute to bone marrow edema (BME),
the exact pathogenetic processes are not currently
known [3]. The natural time-course for improvement of
clinical symptoms and normalization in MRI lasts from
3 to 18 months [4]. BMES has been reported to occur in
the knee (BMESK); yet, owing to the small number of
reports on this specific entity, little is known about the
optimal treatment of patients with this condition [1].
In general, the therapeutic approach to BMESK is based
on its suspected etiology and ranges from various symp-
tomatic therapies to core decompression (CD) [1–5].
Non-surgical treatments that have been reported as being
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beneficial include reduction in weight-bearing load of the
joint, analgesic and anti-inflammatory medication, gluco-
corticosteroids, bisphosphonates, calcium channel blockers
and prostaglandin inhibitors (e.g. iloprost) [2–4]. Un-
fortunately, conservative treatment approaches are un-
able to relieve symptoms in some cases [1, 5]. Surgical
CD, which reduces pain through relief of intraosseous
pressure, is usually used as the last resort, particularly
as the condition is self-limiting in the majority of pa-
tients [1, 5, 6]. BMESK can be associated with a pro-
longed course of disease and invalidity, non-response to
treatment and disease recurrence. Surgical intervention
is a costly approach and carries with it the risk of compli-
cations including wound infection, hematoma formation,
reflex sympathetic dystrophy, and bone fractures associ-
ated with bone tunnel drilling [1, 2, 6]. Various treatments
have been proposed in an attempt to shorten the natural
course of the disease, which is invariably associated with
severe and long-lasting disability [5, 7]. However, there is
a need for an effective and non-invasive method of treat-
ing BMESK.
In musculoskeletal disorders, the effectiveness of extra-
corporeal shock wave therapy (ESWT) has been widely
recognized and recent research supports its use in the
treatment of the first stages of avascular osteonecrosis of
the proximal femur and in other conditions where bone
marrow edema is present [7–9]. The mechanism by which
shock wave therapy works is being increasingly broad and
in-depth study. It has been shown to activate many cellu-
lar processes critical to neovascularization and tissue re-
generation. Previous reports have shown that shock wave
has also been reported to control inflammatory processes
and facilitate bone reparative processes [7–11].
On this basis, we performed a prospective rando-
mised controlled study to evaluate the effectiveness of
ESWT in normalizing the symptoms and imaging features
of BMESK. We compared 2 therapies, topical ESWT
chosen as the observation group versus iloprost and bis-
phosphonate treatment served as the control group. We
hypothesized that topical ESWT would result in rapid
pain relief and functional improvement without substan-
tial complications.
Methods
This prospective randomised controlled study was
approved by the Ethics Committee of China-Japan
Friendship Hospital (China-Japan Friendship Hospital
drug / device clinical trials Ethics Committee). Written
consents were provided by the patients to be stored in the
hospital database and be used for clinical research.
Clinical data
In this single center study, 40 consecutive patients with
MRI-confirmed primary BMESK were prospectively
matched by age and diagnosis from June 2011 to May
2013 (Table 1). All patients provided written informed
consent to participation in this prospective trial, and
the study was approved by the Scientific Review Board
of our institution. Using computer-generated random
assignment concealment with sealed envelopes, patients
were allocated to receive ESWT (Group A) (n = 20) or
alendronate sodium tablets (70 mg po qw; Merck & Co.,
Inc.; Peking) and alprostadil (10 μg ivgtt qd; Peking Tide
Pharmaceutical Co., Ltd.; Peking) (Group B) (n = 20). Ex-
clusion criteria were BME with any finding of avascular
necrosis (demarcation) or advanced osteoarthritis (Ahlbäck
grade 3 or 4). Patients who had received any previous
treatment were also excluded, along with those who
had contraindications for ESWT [8]. The average time-
period between the onset of symptoms and the begin-
ning of treatment was 3.8 weeks (range 2–8 weeks). All
patients were mobilized with partial weight-bearing and
walking aids for 6 weeks and analgesics on demand
with restrictions for impact sports such as sprinting or
jumping. The groups were examined clinically and evalu-
ated with relevant scoring systems by a single examiner:
the Visual Analog Scale for pain (VAS, 100 mm), the
Western Ontario and McMaster University (WOMAC)
Osteoarthritis Index and the SF-36 scores were assessed
before treatment (t0), at 1 months (t1), 3 months (t2),
6 months (t3) and 1 year (t4) post-treatment. MRI scans
as well as plain radiographs were obtained before, and
6 months and 1 year after, therapy. The mean follow-up
period was 13 (12–18) months. An experienced radiologist
evaluated the area of edema on one slide with the most
obvious edema of the resulting MRI films with the same
fluid sensitive sequence using the PACS software (Kodak
version 11.0, MA, USA) to verify whether the edema le-
sion showed unchanged, reduced or regressed completely.
Shock wave treatment
The shock wave treatment was applied using an Elec-
tromagnetic Shock Wave Emitter (Dornier Compact
DELTA II; Germany), with a penetration depth of be-
tween 0 and 150 mm and a focus diameter of 4 mm.
Table 1 Patients characteristics
Characteristics Group A (n = 20) Group B (n = 20)
Female, n (%) 9 (45) 11 (55)
Age, years 41.6 ± 9.7 45.1 ± 8.9
Height, m 1.65 ± 0.21 1.68 ± 0.32
Weight, kg 64.2 ± 6.3 67.4 ± 8.6
BMI, kg/m2 25.5 ± 3.7 24.9 ± 5.4
IBST, weeks 2.9 ± 2.7 3.2 ± 1.9
Duration of follow-up, months 12.1 ± 2.5 13.0 ± 1.8
Note: BMI Body Mass Index, IBST Interval between the onset of symptoms and
the beginning of treatment
Gao et al. BMC Musculoskeletal Disorders  (2015) 16:379 Page 2 of 8
Shock waves were focused around (on the margins of )
the femoral head under radiographic guidance. The
treatment area was prepared with a coupling gel to
minimize the loss of shock wave energy at the interface
between the head of the device and the skin. In Group A,
patients were subjected to high-energy ESWT [12, 13],
and the parameters are prepared and used as follows:
number of levels, 3–4; at a high energy flux density (EFD)
of > 0.44 mJ/mm2 (level 3); 3000–4000 impulses at a fre-
quency of 2–3 Hz. Each patient underwent two therapy
sessions (the time interval between successive procedures
was 1 week). The number of the frequency selected de-
pends on the patient’s condition.
Statistical Analysis
All data analyses were performed using SPSS version
16.0.0 software (SPSS; Chicago, IL, USA). The means
and standard deviations (SD) were calculated for all pa-
tients, and 95 % confidence intervals (CIs) were deter-
mined. For within-group comparisons, we performed a
paired t-test. A probability (P) value < 0.05 was consid-
ered to be of statistical significance.
Results
From June 2011 through May 2013, 56 patients with
MRI-confirmed BMESK with a single group of surgeons
were screened and assessed for eligibility, as 9 patients
were eliminated by exclusion criteria. 6 patients were ex-
cluded from the trial due to patient decline of enrollment.
A total of 41 patients were randomized to receive the
study treatment using a block randomization technique.
After randomization, one patient withdrew consent prior
to the study, thus resulting in 40 patients (group A: 20 pa-
tients for ESWT; group B: 20 patients for drugs) that were
included in the statistical analysis of our trial (Fig. 1).
Clinical results
Compared with Group B, all patients in Group A
showed a greater and earlier improvement in VAS,
WOMAC Osteoarthritis Index and SF-36 score at t1–3
(1, 3 and 6 months post-treatment) after therapeutic
intervention (P < 0.05), and almost all patients in Group
A continued to improve over the follow-up period (Figs. 2,
3 and 4). Significant improvement in the VAS was ob-
served in Group A, from 6.7 ± 1.1 points to 2.6 ± 1.1
points at 1 month (t1) and to 1.1 ± 0.7 points at 3 months
(t2) after therapeutic intervention (P < 0.001) (Fig. 2).
Gradual improvement in the VAS was shown in Group B,
from 6.1 ± 1.7 points to 4.9 ± 2.0 points at 1 month (t1)
and to 2.8 ± 1.3 points at 3 months (t2) after therapeutic
intervention (P < 0.05) (Fig. 2). The mean improvement
between t2 and t3 and between t3 and t4 in both groups
was not statistically significant.
Significant improvements in the WOMAC Osteoarth-
ritis Index were observed in both groups (Fig. 3). Group A
improved from 54.3 ± 10.1 points to 26.6 ± 12.0 points at
1 month (t1), to 10.9 ± 11.1 points at 3 month (t2), to 9.8
± 12.3 points at 6 months (t3) and to 9.7 ± 11.0 points at
Fig. 1 The CONSORT flowchart in the trial
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1 year (t4) after ESWT (P < 0.01) (Fig. 3). Group B showed
significant improvement, from 56.9 ± 11.5 points to 38.7 ±
10.1 points at 1 month (t1), to 27.8 ± 16.7 points at
3 months (t2), to 24.6 ± 11.3 points at 6 months (t3) and
to 20.9 ± 17.8 points at 1 year (t4) after drug therapy (P <
0.05) (Fig. 3). There was a trend towards a greater im-
provement in Group A than in Group B; this effect was
statistically significant (P < 0.01).
The SF-36 score improved significantly in both groups
at t1 (1 months) (Fig. 4). There was a statistically signifi-
cant difference in the physical component of the SF-36
score between the groups at 3 months (P < 0.05) (Fig. 4a).
However, there was no significant difference in the men-
tal component of the SF-36 score between the groups at
3 months (P > 0.05) (Fig. 4b). Comparison of the results
within and between the two groups revealed that there
were no significant differences in the VAS, WOMAC
Osteoarthritis Index and SF-36 score at 1 year post-
intervention (P < 0.05).
Radiological results
The MRI findings demonstrated the progressive regres-
sion of the BME. MRI scans of both groups showed
that the patients in Group A had a higher incidence of
distinct reduction and complete regression of BME at
6 months (95 vs. 65 %; P = 0.018). The MRI at 6 months
follow-up in Group A showed a reduction in BME in
35 % (7/20) of all patients and complete regression in
65 % (13/20). In Group B, there was a reduction in
BME in 40 % (8/20) of all patients and complete regres-
sion in 25 % (5/20). However, the MRI at 1 year follow-
up showed complete regression in all patients in Group
A (100 %) and most patients in Group B (90 %); two
cases in Group B continued to normalize over the sub-
sequent follow-up period (18 months).
Side-effects
Only minor complications occurred after ESWT, such
as transient soft tissue swelling or minor bruising. No
other adverse effects were noted. No clinically detect-
able neuromuscular, systemic, or device-related adverse
effects were observed in the ESWT group. Following al-
prostadil administration, headache was reported in three
patients and a facial rash in two patients; these symptoms
occurred during the first 1 h of infusion. No adverse
events were detected with alendronate.
Fig. 2 The development of the VAS during therapeutical intervention between two Groups
Fig. 3 The development of the WOMAC score during therapeutical intervention between two Groups
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Case report
Case 1
Bone Marrow Edema Syndrome (BMES) of the left
knee was diagnosed in a 62-year-old, male professor.
ESWT rapidly produced positive effects with regard to
both pain and BME. The VAS score dropped from 8
points preoperatively to 2 points at 1 months post-
treatment. Symptoms of pain were significantly alleviated.
In addition to improvements in the WOMAC Osteoarth-
ritis Index, SF-36 score and VAS, MRI showed a signifi-
cant reduction in edema between the pre-treatment
(Fig. 5a) and 6-months post-treatment (Fig. 5b) time-
points. The patient has provided consent to publish the
information contained in this case report, as well as Fig. 5
and the accompanying legend.
Discussion
Our study shows that ESWT can also relieve a great deal
of discomfort for BMESK patients. Furthermore, the mean
VAS showed a dramatic improvement from pre-treatment
values at all follow-up time-points in ESWT patients,
especially at t1 (1 month). The clinical improvement in
WOMAC Osteoarthritis Index and SF-36 scores ob-
served following ESWT was obvious in most patients at
1 month post-treatment (P < 0.05). These scores im-
proved significantly earlier than those in the drug
control group (P < 0.05), in which improvements were
observed mainly at 3 months post-intervention. At this
point, all patients had already regained a significant
level of autonomy in their daily lives with a marked re-
duction in pain, which correlated with the progressive
normalization of MRI features. Although the final out-
comes of the various conservative treatments currently
used are similar to those observed in some studies of
ESWT, it is important to note that ESWT is a simple,
non-invasive treatment that does not require the ad-
ministration of pharmacological drugs, thus avoiding
the reported potential side-effects [8]. Our treatment
protocol required only two therapy sessions as opposed
to the time-consuming extended treatments such as
pharmacological drugs.
Primary bone marrow edema syndrome is a rare, but
underdiagnosed source of pain which mainly occurs
around joints of the lower extremities [2, 5, 14]. There
is still debate regarding the pathogenesis and implica-
tions of BME, and this is reflected in the lack of a gold
standard in the treatment of this condition. Because of
the reversibility of BME, conservative treatment has
been recommended, including reduction of weight-
bearing load, analgesic and anti-inflammatory medica-
tion and physiotherapy [5, 6, 11, 14, 15]. Reports of the
use of bisphosphonates relate predominantly to their
Fig. 4 The development of the SF-36 score during therapeutical intervention between two Groups (a, physical component; b, mental component)
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role in the treatment of BMES. Intravenous prostacyclin
and bisphosphonate can be used to achieve a reduction in
BME, with a considerable improvement in the accom-
panying symptoms [2]. Prostacyclin improves tissue blood
supply in a variety of situations through multiple mecha-
nisms, including vasodilatation and inhibition of platelet
aggregation [2, 5]. Pain relief and rapid regression of BME
is attributed to the action of prostacyclin in dilating vessels
and reducing capillary permeability [14]. Bisphosphonates
have been shown to improve bone density in a variety of
conditions [2]. Unfortunately, conservative treatment ap-
proaches take too long time or are unable to relieve symp-
toms in some cases [1, 5]. In attempting to shorten the
clinical course BMES, which is invariably associated with
severe and long-lasting disability, various treatments have
been proposed [5, 7, 14]. Core decompression has been
reported as the standard surgical treatment of recurrent
or persistent painful BMES, particularly of the hip, and
improves symptoms of pain through relief of intraoss-
eous pressure [1, 2, 5, 7, 16, 17]. However, surgery is
costly and associated with risks [2, 5, 6]. A consensus is
required regarding the importance of an early treat-
ment to relieve pain and to avoid weakening the bone
trabeculae, which could potentially lead to a collapse or
fracture of the subchondral bone [8]. Some consider
that surgery is too invasive for a self-limiting disease
with a variable clinical course [2, 8, 15].
ESWT has been shown to be effective in treating many
orthopedic disorders, including osteonecrosis [1, 9, 18].
Clinical trials have also highlighted the effectiveness of
ESWT in treating the early stages of avascular necrosis,
reducing bone edema and pain [8, 18]. There are cur-
rently few reports addressing the use of ESWT in BMES
of the hip [7, 8, 11]. However, the exact mechanism by
which ESWT operates remains relatively unknown.
Tischer et al. demonstrated the amount of new bone for-
mation is directly dependent on the applied EFD [10].
Too low or too high defined energy dose for shock wave
applications is disadvantageous to formation of new
bone. So it is very important to select an appropriate
EFD, and it can improve the efficacy of shock wave and
minimize topical side effects [10]. The close anatomical
and functional links between vascular elements, marrow
stromal and active bone cells may explain the positive
effects of ESWT on bone metabolism [8]. ESWT, as one
of the most frequently used physical therapies, seems to
be able to control inflammatory processes and to facili-
tate bone reparative processes as well as to activate
many cellular processes critical to neovascularization
and tissue regeneration [7–11]. Some animal studies
have demonstrated positive results in the application of
ESWT on osteonecrosis with a better induction of tissue
ingrowth and neovascularization; it is associated with in-
creased expression of angiogenic growth factors, includ-
ing BMP-2, vessel endothelial growth factor (VEGF),
endothelial nitric oxide synthase (eNOS), and proliferat-
ing cell nuclear antigen (PCNA), and it promotes cell
proliferation and osteogenesis [19–21]. BMP-2 is a key
mediator of bone development and repair through its
capacity to mobilize osteoprogenitor cells. Increased
expression of BMP-2 has been identified in femoral
heads treated with ESWT, thereby promoting osteo-
blastic differentiation processes and resulting in bone
formation [22]. VEGF, as a specific mitogenic factor for
vascular endothelial cells, may be involved in the mech-
anism of the positive effects of ESWT. It stimulates the
Fig. 5 Pre- (a) and 6 months posttreatment (b) T2-weighted images showing the normalization of a large bone marrow edema within the medial
femoral condyle of the left knee, in a 62-year old male patient. (Note: The patient consented to publish the specific information.)
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proliferation of endothelial cells, promotes neovascular-
ization, and increases vascular permeability [23].
Finally, eNOS promotes neovascularization [18]. It is
reasonable to speculate that neovascularization plays a
role in the improvement in the blood supply to the
femoral head and may promote bone regeneration in
cases of BMES [24, 25]. Early studies indicate that a
similar effect to that of vasoactive drugs can be
obtained with ESWT [9, 17]. The neo-angiogenetic
effect of ESWT appears to reduce the time to symptom
remission. ESWT showed significantly better clinical
results and BME regression rates in MR-imaging
compared to conservative treatment in combination
with partial weight-bearing in the treatment of BMESK
and shortens the natural course of the disease. Besides,
ESWT might have the potential to avoid the need for
surgical intervention according to previous studies [26, 27].
The pathophysiologic mechanism that is responsible
for the dramatic pain reduction in all BMES patients
following ESWT, is still unclear. ESWT for the manage-
ment of BMES is easy to perform in a clinical setting
and does not carry risk for the patients. Our results in-
dicate that ESWT of BMES with increased bone turn-
over reduces pain by eliminating the BME and shortens
the natural course of the “self-limiting disease”. The
high regression rate of BME with no bone osteonecrosis
present at the follow-up MRI in this study also supports
the hypothesis that BMES is a distinct clinical entity, ra-
ther than an early form of bone osteonecrosis [14, 28, 29].
This study was conducted according to the CON-
SORT guidelines [30] with a rigorous study design, a
clinically feasible intervention and good adherence to
the programme. There are limitations associated with
this study. The number of patients in the study was
relatively small, and the follow-up time was relatively
short, but similar to prior studies on this subject.
The functional improvement in the knee was assessed
subjectively using the VAS and functional scores, but no
objective measures were utilized. However, the results of
this study warrant confirmation in larger trials with longer
follow-up periods although these studies are complicated
by the off-label-use of ESWT. These patients with ESWT
had not gotten any iloprost and bisphosphonate. However,
we will consider combining topical ESWT with iloprost
and bisphosphonate in the treatment of BMESK in future
studies.
Conclusions
In summary, ESWT is an effective, reliable, and non-
invasive technique for rapid treatment of BMESK,
followed by a progressive normalization of the MRI ap-
pearance. ESWT represents an innovative technology
applicable to orthopedics, although further develop-
ment is required. Further exploration of its mechanisms
and prospects would be worthwhile, as it has the poten-
tial to resolve the suffering of BMESK patients rapidly
and effectively.
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